PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127⁺ and KLRG1⁺ CD8 T cells.

ABSTRACT: The combination of PD-1 blockade with neoadjuvant chemotherapy (NAC) has achieved unprecedented clinical success in non-small cell lung cancer (NSCLC) compared to NAC alone, but the underlying mechanisms by which PD-1 blockade augments the effects of chemotherapy remain incompletely elucidated. Single-cell RNA sequencing was performed on CD45⁺ immune cells isolated from surgically resected fresh tumors of seven NSCLC patients receiving NAC or neoadjuvant pembrolizumab and chemotherapy (NAPC). Multiplex fluorescent immunohistochemistry was performed on FFPE tissues before and after NAC or NAPC from 65 resectable NSCLC patients, and results were validated with GEO dataset. NAC resulted in an increase only of CD20⁺ B cells, whereas NAPC increased the infiltration of CD20

SUBMITTER: Hui Z 

PROVIDER: S-EPMC10213055 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature